Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy-Reference-Cited by-同舟云学术

Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy

Published:2012-03 Issue:3 Volume:23 Page:610-617
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Campone M.,Bondarenko I.,Brincat S.,Hotko Y.,Munster P.N.,Chmielowska E.,Fumoleau P.,Ward R.,Bardy-Bouxin N.,Leip E.,Turnbull K.,Zacharchuk C.,Epstein R.J.

Funder

research funding from Wyeth Research, which was acquired by Pfizer Inc in October 2009

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/23/3/610/604537/mdr261.pdf

Reference24 articles.

1. Multicenter phase II study of oral capecitabine (Xeloda(“)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy;Reichardt;Ann Oncol,2003

2. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual;Singletary;CA Cancer J Clin,2006

3. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009;Goldhirsch;Ann Oncol,2009